Biocon And Viatris Get CRL From FDA On Insulin Aspart
Biosimilar Rival To NovoLog Already Approved In Europe As Kixelle
Executive Summary
Viatris and partner Biocon have suffered a setback over their proposed insulin aspart biosimilar rival to NovoLog in the US, after the FDA issued a CRL relating to the filing.
You may also be interested in...
Biocon ‘Strongly Denies’ Allegations Of Bribery Amid Reports
India’s Biocon has issued a response after a local English-language daily reported allegations that the company and one of its officials was involved in bribing the Joint Drugs Controller to waive Phase III clinical trial data for its proposed NovoLog (insulin aspart) biosimilar.
Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars
Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.
Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars
Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.